Updated on 16 February 2017
Singapore: Mundipharma and Helsinn Group have expanded their collaboration, signing amendments to licensing and distribution agreements for anti-emetic prophylactic agents ALOXI and AKYNZEO to cover a host of additional markets.
Chemotherapy induced nausea and vomiting (CINV) is one of the most common side effects of cancer chemotherapy. The prevention of CINV has been refined in the major international antiemetic guidelines over the past several decades and the combination of antiemetic agents with different mechanisms of actions are now recommended for the prevention of CINV.
ALOXI (palonosetron) is a 5-HT3 receptor antagonist indicated as single agent for the prevention of CINV. AKYNZEO is the first fixed combination oral agent targeting two critical signalling pathways associated with CINV by combining palonosetron with netupitant, the new highly selective NK1 receptor antagonist, in a single capsule.
Under the terms of the arrangement, Mundipharma has acquired all the rights for marketing, promotion, distribution and sales of ALOXI and AKYNZEO for an additional 30 countries in Africa as well as Iran, Pakistan and Indonesia.
Additionally, Mundipharma has also secured the rights for AKYNZEO for Argentina, Uruguay and Paraguay.